MET and non-small cell lung carcinoma: At present, METex14 skipping is the sole therapeutic target for NSCLC patients with MET pathway disorders, and its related targeted drugs such as carmatinib, tepatinib, and sevotinib have completely changed the treatment mode and prognosis of patients [6].